1
|
Han B, Liu W, Du J, Liu H, Zhao T, Yang S, Wang S, Zhang S, Liu B, Liu Y, Cui F. 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial. Vaccines (Basel) 2021; 9:1407. [PMID: 34960153 PMCID: PMC8705985 DOI: 10.3390/vaccines9121407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 11/22/2021] [Accepted: 11/26/2021] [Indexed: 12/04/2022] Open
Abstract
BACKGROUND In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. METHODS In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. RESULTS The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. CONCLUSIONS At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory.
Collapse
Affiliation(s)
- Bingfeng Han
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China; (B.H.); (H.L.); (T.Z.); (S.Z.)
| | - Wu Liu
- Jingyuan County Center for Disease Control and Prevention, Baiyin 730600, China; (W.L.); (S.Y.)
| | - Juan Du
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China; (J.D.); (B.L.); (Y.L.)
| | - Hanyu Liu
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China; (B.H.); (H.L.); (T.Z.); (S.Z.)
| | - Tianshuo Zhao
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China; (B.H.); (H.L.); (T.Z.); (S.Z.)
| | - Shubo Yang
- Jingyuan County Center for Disease Control and Prevention, Baiyin 730600, China; (W.L.); (S.Y.)
| | - Shuai Wang
- Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China;
| | - Sihui Zhang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China; (B.H.); (H.L.); (T.Z.); (S.Z.)
| | - Bei Liu
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China; (J.D.); (B.L.); (Y.L.)
| | - Yaqiong Liu
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China; (J.D.); (B.L.); (Y.L.)
| | - Fuqiang Cui
- Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China; (J.D.); (B.L.); (Y.L.)
| |
Collapse
|
2
|
Immune response to different types of hepatitis B vaccine booster doses 2–32 years after the primary immunization schedule and its influencing factors. Int J Infect Dis 2020; 93:62-67. [DOI: 10.1016/j.ijid.2020.01.047] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Revised: 01/22/2020] [Accepted: 01/23/2020] [Indexed: 12/15/2022] Open
|
3
|
Zhao YL, Han BH, Zhang XJ, Pan LL, Zhou HS, Gao Z, Hao ZY, Wu ZW, Ma TL, Wang F, Li Q, Bi SL, Ma JC. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infect Dis 2019; 19:482. [PMID: 31146699 PMCID: PMC6543564 DOI: 10.1186/s12879-019-4134-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2019] [Accepted: 05/27/2019] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND To assess the immune persistence conferred by a Chinese hamster ovary (CHO)-derived hepatitis B vaccine (HepB) 17 to 20 years after primary immunization during early life. METHODS Participants born between 1997 and 1999 who received a full course of primary vaccination with HepB (CHO) and who had no experience with booster vaccination were enrolled. Blood samples were required from each participant for measurement of hepatitis B surface antibody (anti-HBs), surface antigen and core antibody levels. For those who possessed an anti-HBs antibody < 10 mIU/mL, a single dose of HepB was administered, and 30 days later, serum specimens were collected to assess the booster effects. RESULTS A total of 1352 participants were included in this study. Of these, 1007 (74.5%) participants could retain an anti-HBs antibody ≥10 mIU/mL, with a geometric mean concentration (GMC) of 57.4 mIU/mL. HBsAg was detected in six participants, resulting in a HBsAg carrier rate of 0.4% (6/1352). Of those participants with anti-HBs antibodies < 10 mIU/mL, after a challenge dose, 231 (93.1%) presented an anti-HBs antibody ≥10 mIU/mL, with a GMC of 368.7 mIU/mL. A significant increase in the anti-HBs positive rate (≥ 10 mIU/mL) after challenge was observed in participants with anti-HBs antibodies between 2.5 and 10 mIU/mL and participants boosted with HepB (CHO), rather than those with anti-HBs antibodies < 2.5 mIU/mL and those boosted with HepB (SC). CONCLUSION Since satisfactory immune protection against HBV infection conferred by primary vaccination administered 17-20 years ago was demonstrated, there is currently no urgent need for booster immunization.
Collapse
Affiliation(s)
- Yu-Liang Zhao
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China.
| | - Bi-Hua Han
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| | - Xin-Jiang Zhang
- Zhengding County Center for Disease Control and Prevention, Zhengding, 050800, People's Republic of China
| | - Lu-Lu Pan
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| | - Hai-Song Zhou
- Zhengding County Center for Disease Control and Prevention, Zhengding, 050800, People's Republic of China
| | - Zhao Gao
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| | - Zhi-Yong Hao
- Zhengding County Center for Disease Control and Prevention, Zhengding, 050800, People's Republic of China
| | - Zhi-Wei Wu
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| | - Tian-Li Ma
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| | - Feng Wang
- Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Changing District, Beijing, 100052, People's Republic of China
| | - Qi Li
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| | - Sheng-Li Bi
- Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Changing District, Beijing, 100052, People's Republic of China
| | - Jing-Chen Ma
- Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, 97 Huai'an East Road, Yuhua District, Shijiazhuang, 050021, Hebei Province, People's Republic of China
| |
Collapse
|
4
|
Boa A, Douba A, N Guessan TB, Menan H, Attia A, Ouassa T, Bénié JBV, Abokon A, Dosso M, Aholi P, Timité-Konan M, Abauleth RY, Bissagnéné E, Aka J, Yavo JC, Sylvain BJ, Ouattara GS, Ekra DK, Sow K, Kouassi JNG, Ahoussou EMK, Dally RK. [A plea for introduction of hepatitis B vaccination at birth in Côte d'Ivoire]. SANTE PUBLIQUE (VANDOEUVRE-LES-NANCY, FRANCE) 2017; 29:751-760. [PMID: 29384309 DOI: 10.3917/spub.175.0751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The Côte d'Ivoire National Immunization Technical Advisory Group 2015 work plan included elaboration of an opinion on inclusion of hepatitis B vaccination at birth in the Expanded Program on Immunization (EPI) in Côte d'Ivoire. A task force was set up to conduct this assessment according to a systematized method. The task force analysed scientific articles on the burden of hepatitis B in Côte d'Ivoire, the burden of mother-child transmission, the impact of hepatitis B vaccination at birth in countries which have adopted this strategy, the efficacy and safety of hepatitis B vaccine in newborns, the cost-effectiveness of hepatitis B vaccination at birth, and the best strategy to introduce hepatitis B vaccination at birth in the EPI. The National Immunization Technical Advisory Group of Côte d'Ivoire finally recommended introduction of a dose of hepatitis B vaccine at birth in the context of the Expanded Program on Immunization with maintenance of three doses of pentavalent vaccine (DPT-HepB-Hib) at 6, 10, and 14 weeks of age.
Collapse
|
5
|
Wang F, Ma J, Hao Z, Zhang Z, Zhang X, Gao Z, Bi S, Shen L, Qiu F, Zhao Y. The long-term efficacy of Chinese hamster ovary cell derived hepatitis B vaccine after being used for 14-16 years in Chinese rural communities. Vaccine 2014; 33:294-7. [PMID: 25454089 DOI: 10.1016/j.vaccine.2014.11.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/24/2014] [Accepted: 11/17/2014] [Indexed: 12/29/2022]
Abstract
OBJECTIVE To evaluate the long-term efficacy of Chinese hamster ovary (CHO) cell derived hepatitis B vaccine after being used for 14-16 years in country community in Hebei province in China. METHOD A cross-sectional investigation was carried out in 3 of 7 randomly selected rural communities in Zhengding County in 2013. The children who were born between 1997 and 1999 and were vaccinated with three doses of CHO-derived hepatitis B vaccine were eligible to participate in the study. Their sera samples were tested for HBV serological markers. For HBsAg positive children, their historical results were compared, in order to see whether these were new infections. RESULTS Among the 920 participating children, the prevalence of HBsAg, anti-HBs and anti-HBc were 0.65%, 73.15% and 1.20% respectively. The differences between birth-year groups were not significant. When compared with baseline, the vaccine efficacy was 94.2% and the anti-HBs titers of 668 children with sole anti-HBs positivity were 178.8 mI U/ml. By comparing with historical data, no new infection was found in this latest survey. Among 6 mothers of HBsAg positive children, 4 were HBsAg positive, 1 was negative and 1 was unknown. CONCLUSION The long-term efficacy of the CHO derived hepatitis vaccine is good and stable for 14-16 years after vaccination. A booster dose seems not necessary. Implementing mother-newborn blocking measures for newborns from HBsAg carrier mothers is urgently needed in the future.
Collapse
Affiliation(s)
- Feng Wang
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, PR China
| | - Jingchen Ma
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang 050021, PR China
| | - Zhiyong Hao
- Zhengding County Center for Disease Control and Prevention, Zhengding 050800, PR China
| | - Zhiyong Zhang
- Zhengding County Center for Disease Control and Prevention, Zhengding 050800, PR China
| | - Xinjiang Zhang
- Zhengding County Center for Disease Control and Prevention, Zhengding 050800, PR China
| | - Zhao Gao
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang 050021, PR China
| | - Shengli Bi
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, PR China
| | - Liping Shen
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, PR China
| | - Feng Qiu
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping District, Beijing 102206, PR China.
| | - Yuliang Zhao
- Hebei Province Center for Disease Control and Prevention, Shijiazhuang 050021, PR China.
| |
Collapse
|
6
|
Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol 2013; 28 Suppl 1:7-10. [PMID: 23855289 DOI: 10.1111/jgh.12220] [Citation(s) in RCA: 239] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/15/2013] [Indexed: 12/12/2022]
Abstract
A high rate of chronic hepatitis B virus (HBV) infection in China is mainly caused by perinatal or early childhood transmission. Administration of universal HBV vaccination in infants has led to a dramatic decrease in HBV epidemiology, with hepatitis B surface antigen (HBsAg) prevalence declining from 9.75% in 1992 to 7.18% in 2006. The major HBV genotypes are B and C, with B being more prevalent in the southern part and C more prevalent in the northern part of China. A national survey carried out in 1992 showed that the hepatitis C virus (HCV) infection rate was 3.20% in general population in China. After implementation of mandatory HCV screening for blood transfusion and other precautions to prevent blood-borne disease since 1993, the new cases of HCV infection associated with blood or blood product has become very rare. Although the anti-HCV prevalence would be much higher in high-risk groups, a survey carried in 2006 showed that the anti-HCV prevalence rate was only 0.43% in general population. This sharp decline in HCV infection rate was mainly due to stringent administration and monitoring of blood donors and blood products, but may also be related to the remarkably improved specificity of anti-HCV test. The predominant HCV genotype in China is genotype 1b (60-70%), and the host interleukin-28b rs12979860 CC genotype is very frequent in Chinese population (over 80%).
Collapse
Affiliation(s)
- Yan Cui
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | | |
Collapse
|
7
|
Thornthwaite JT, Shah H, Shah P, Respess H. The Natural Killer Cell: A Historical Perspective and the Use of Supplements to Enhance NKC Activity. ACTA ACUST UNITED AC 2012. [DOI: 10.4236/jibtva.2012.13004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|